GSK receives U.S. FDA approval for neladalkib, marketed as Nelkarmi, the second lung-cancer drug tied to its Nuvalent deal. The FDA grants accelerated approval for use in ALK-positive non-small cell lung cancer.

Across the outlets, the core facts are consistent: the approval is FDA action, the drug is neladalkib (Nelkarmi), and the indication is ALK-positive non-small cell lung cancer. The different coverage primarily reflects how each publisher frames the relationship to the Nuvalent transaction and how it names the approval outcome (e.g., emphasising “wins” or highlighting “accelerated approval”).